1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > A Competitive Analysis of the Global Breast Cancer Therapeutics Market : A New Class of Targeted Therapeutics Offers Novel Treatment Modalities to Treat Difficult Breast Cancers

A Competitive Analysis of the Global Breast Cancer Therapeutics Market : A New Class of Targeted Therapeutics Offers Novel Treatment Modalities to Treat Difficult Breast Cancers

  • March 2015
  • -
  • Frost & Sullivan
  • -
  • 68 pages

Summary

Table of Contents

Executive Summary

•The global breast cancer therapeutics market is divided into x segments: hormonal therapy, targeted therapy, chemotherapy, and other therapy (for example, novel drugs in development).
•About x hormonal therapies are available to treat breast cancer. The most common ones are aromatase inhibitors and selective oestrogen receptor modulators (SERMs).
•Only x approved targeted treatments are available in the U.S. market, namely, Herceptin (Roche) and Tykerb (GSK). 2 more drugs, Kadcyla (Roche) and Perjeta (Roche), were approved in 2013. At present, Roche dominates the global breast cancer therapeutics market.
•Although there are approximately x drugs indicated for the treatment of breast cancer, there remains a large unmet need to treat patients. As a result, the breast cancer pharmaceutical pipeline is strong, with about x drugs in development.
•Chemotherapy remains the most important class of drugs for breast cancer treatment; however, the trend of using targeted drugs is on the rise.
•Combination treatment is a focus for companies with breast cancer treatment in development; however, drugs that held potential in Phase 2 trials failed to make an impact in Phase 3, forcing companies to re-design trials or stop the research programme.
•Between 2015 and 2017, the key drugs to watch out for will be ABT-888 (AbbVie), NeuVax (Galena Biopharma), Palbociclib (Pfizer), NKTR-102 (Nektar), Nexavar (Bayer/Onyx), and CT-P6 (Celltrion).
•Palbocilib (Pfizer), LY2835219 (Eli Lilly), and LEE011(Novartis) are the most exciting drugs to look out for as they represent the cyclin-dependent kinases (CDK) unique class of drug inhibitors, a first of a kind from a breast cancer therapeutics perspective.
•Palbocilib is a CDK inhibitor oral drug that has been approved for filing and granted priority review by the U.S. Food and Drug Administration (FDA). If approved, this treatment will benefit patients as a first-line therapy (in combination with letrozole).
•LY2835219 (Eli Lilly) and LEE011 (Novartis) are the other key CDK inhibitors expected to compete with Palbocilib. Although no preliminary data is available in terms of Phase 3 trials, at present, they are anticipated with positive enthusiasm from their developers.
•In 2014, market size was estimated at $ x billion; the market is expected to witness a compound annual growth rate (CAGR) of x % over the next x years.

Physician Guidelines to Breast Cancer Therapy—Her 2 Positive

•Herceptin therapy, along with chemotherapy combination, such as Xeloda and Tykerb, represents the standard treatment regime for Her 2-positive breast cancer.
•This standard treatment is also being administered subcutaneously to reduce run time. Most breast cancer patients benefit from this therapy, demonstrating an affirmative response to Her 2 positive.
•New versions, such as Kadcyla and Perjeta, leverage Roche’s proprietary technology.

Physician Guidelines to Breast Cancer Therapy—ER or PR Positive

•Hormone-positive patients represent the next largest market and are usually treated with Faslodex, along with chemotherapeutic agents, such as anthracyclines or taxanes.
• Exemestane is usually prescribed after the failure of Tamoxifen. It also serves as a third-line therapy option for advanced breast cancer patients.

Physician Guidelines to Breast Cancer Therapy— Triple-negative Breast Cancer

•Ideally, anthracyclin or taxane is administered to patients with triple-negative breast cancer as they do not respond to either hormone therapy or Her 2-positive-targeted therapeutics.
•At present, new and promising therapeutic targets, such as CDKs, poly-adenosine ribose phosphates, and epidermal growth factor receptors are being evaluated to develop drugs to fulfil this unmet need.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
OpportunityAnalyzer: Hyperparathyroidism - Opportunity Analysis and Forecasts to 2025

OpportunityAnalyzer: Hyperparathyroidism - Opportunity Analysis and Forecasts to 2025

  • $ 10995
  • Industry report
  • December 2016
  • by GlobalData

OpportunityAnalyzer: Hyperparathyroidism - Opportunity Analysis and Forecasts to 2025 Summary Hyperparathyroidism (HPT) is a common endocrinal disorder characterized by excessive plasma levels of parathyroid ...

PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • December 2016
  • by GlobalData

PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025 Summary Human Epidermal growth factor Receptor type 2 (HER2-) breast cancer is the second ...

PharmaPoint: Hepatitis C Virus (HCV) Therapeutics - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Hepatitis C Virus (HCV) Therapeutics - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • December 2016
  • by GlobalData

PharmaPoint: Hepatitis C Virus (HCV) Therapeutics - Global Drug Forecast and Market Analysis to 2025 Summary Hepatitis C virus (HCV) is a small, enveloped RNA virus that causes acute and chronic infections ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.